USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Atlas Genetics Limited

USPTO PatentsView assignee record - 12 granted patents across 5 technology areas, active 2015–2019. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: C12Q (MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICR).

12
Total patents granted
5
CPC technology areas
14.3
Avg claims per patent
-100%
5-year filing velocity

The verdict

Atlas holds 12 US patents across 5 technology areas, rank #22,229 of 50,000 tracked assignees.

#22,229
of 50,000 US assignees by volume
Top 83%
by Innovation Score (25.3/100)
14.3
avg claims per patent
-100%
filing velocity, last 5 yrs

Portfolio overview

Atlas Genetics Limited has been granted 12 US utility patents between 2015 and 2019, placing Atlas Genetics Limited at rank #22,229 across all assignees tracked by PlainPatent. This portfolio spans 5 distinct Cooperative Patent Classification (CPC) subclasses, averaging 14.3 claims per patent with primary concentration in C12Q (MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICR). As a Foreign Corporation, Atlas Genetics Limited is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 25.3/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 0 grants, compared with 12 in the 2015–2019 window, a -100% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Atlas Genetics Limited's 14.3 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 5 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Atlas Genetics Limited against peers pursuing similar technology classes.

How does Atlas compare?

Granted US patents 2015–2025 versus the largest corporate holders, this company marked ◀

patents

What this shows Atlas holds 12 patents, placing it at rank #22,229 overall, well behind the volume leaders but ahead of the tens of thousands of smaller assignees in the dataset.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Atlas's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

25 Top 83% higher than 17% of 50,000 US assignees

0–10: 687 US assignees (1%). Below this entry. 10–20: 2,527 US assignees (5%). Below this entry. 20–30: 13,162 US assignees (26%). This entry sits in this band. 30–40: 15,294 US assignees (31%). Above this entry. 40–50: 11,491 US assignees (23%). Above this entry. 50–60: 5,058 US assignees (10%). Above this entry. 60–70: 1,537 US assignees (3%). Above this entry. 70–80: 234 US assignees (0%). Above this entry. 80–90: 10 US assignees (0%). Above this entry. 90–100: 0 US assignees (0%). Above this entry. This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2019

0123456 2015201720182019 3
USPTO utility patent grants by year · 2015–2019

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
Atlas Genetics Limited patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 1 8.3%
2017 3 25.0%
2018 5 41.7%
2019 3 25.0%

Patent Moat Analysis

Portfolio Volume Light
Tech Breadth Focused
Claim Depth Standard
Velocity Declining

Where it ranks

Overall rank by patents

#22,229

Across all tracked assignees

Innovation Score

25.3 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Atlas Genetics Limited hold?
Atlas Genetics Limited holds 12 US granted patents filed between 2015 and 2019, spanning 5 technology areas.
What is Atlas Genetics Limited's Innovation Score?
Atlas Genetics Limited has an Innovation Score of 25.3 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Atlas Genetics Limited focus on?
Atlas Genetics Limited's top technology area is C12Q (MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES) with 10 patents. The company has filed patents in 5 CPC subclasses total.
Is Atlas Genetics Limited's patent filing rate increasing or decreasing?
Atlas Genetics Limited's recent filing velocity is -100% compared to the prior five-year period. Filing activity has slowed relative to earlier years.
What does claim depth mean for Atlas Genetics Limited's patents?
Atlas Genetics Limited's patents average 14.3 claims each. This falls within the standard range, providing solid legal coverage.
How is the Atlas Genetics Limited patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

Guides to patent portfolio analysis

How to use this portfolio

Atlas's 12 grants land it in the top 83% by Innovation Score, but volume alone doesn't tell you where the strength sits.

  • Read that count against the largest US assignees before treating it as dominance - Atlas ranks #22,229 of 50,000. Top 50 holders
  • Most of this portfolio concentrates in C12Q - see who else leads that technology area. C12Q leaders
  • Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Explore the patent dataset

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Data sources used on this page
  • USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
  • Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
  • USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.